Tagged with Switzerland

Switzerland Darren Kerr, CEO of Swiss medtech Stratpharma discusses, the company’s roots, its broad portfolio in dermatology, plastic surgery and scar management, as well as its growing international footprint.   We target very different market groups, from government and university teaching hospitals with cutting edge science, to the OTC field and…

Serbia CEO of Health Watch Swiss and general manager at Protonmed Serbia, Themis Moustakas has built a quality company thanks to Swiss practices and an entrepreneurial spirit over the last four years. Moustakas reveals how to best approach the mercurial Serbian market, the trick to bidding on government tenders, and how…

Switzerland Benjamin Rousselot of Swiss ear hygiene specialists Laboratoires Diepharmex discusses the history of the company, new products, and the pros and cons of ‘Swissness’. Laboratoires Diepharmex is a Swiss-based, family pharma outfit, established two decades ago and today very well known internationally for its ear hygiene product line, Audispray. Can…

Switzerland Benjamin Rousselot of Swiss ear hygiene specialists Laboratoires Diepharmex discusses the history of the company, new products, and the pros and cons of ‘Swissness’. Laboratoires Diepharmex is a Swiss-based, family pharma outfit, established two decades ago and today very well known internationally for its ear hygiene product line, Audispray. Can…

Switzerland Jean-François Gouzer, CEO of Scientis Pharma, discusses the company’s origin story, its specialization in skin pigmentation disorders, and future internationalization prospects Could you start by introducing the Scientis Pharma story and how the company was founded? “Switzerland is a great environment to do business and to create and develop a…

Switzerland Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s potential as a ‘test market’ for the company. Can you give our international readers an outline of your background and…

Switzerland Petra Doerr, head of sector communication & networking as well as deputy executive director of Swissmedic, the Swiss surveillance authority for medicines and medical devices, discusses changes to the Swiss regulatory system and harmonizing the organization with its global counterparts. Swissmedic has embarked upon a comprehensive overhaul of its regulations in response…

Switzerland Ryad Dahmani, CEO of Swiss-headquartered cold chain logistics specialists, Cold Chain Vision, discusses the impact of new technology in the logistics industry, the importance of quality controls in the transportation of vaccines and why Cold Chain Vision is a name worth remembering for the future. Could you please start by…

Switzerland Stefan Frefel, CEO of Bilfinger Industrial Services in Switzerland, outlines Bilfinger’s core offering of maintenance and engineering services to the pharmaceutical industry, the importance of the Swiss affiliate to the global group, and how the company is positioning itself at the forefront of digital disruption and other new industry trends.…

Switzerland Jonathan Koch, group president R&D Laboratories at Swiss-based CRO, Covance, explains how the integration process with LabCorb has progressed over the last two years, Covance’s embrace of digitally disruptive technologies, and becoming a “flexible service provider.” Two years on from LabCorp’s headline-making acquisition of Covance, how has the integration process…

Switzerland Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?”   We aspire to move the company and the relationship with our customers from being a functional service provider to the strategic partner…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…